Impact of Clinical Pharmacy Services on Medication Cost and Hospitalization Rates in Hemodialysis Patients

End Stage Renal Disease Clinical Trial

Official title: Impact of Clinical Pharmacy Services on Medication Cost and Hospitalization Rates in Hemodialysis Patients

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to evaluate the effects of pharmaceutical care interventions in the ambulatory hemodialysis patients over a one-year period. Cost containment occurs through pharmaceutical care interventions designed to identify and ameliorate drug-related problems (DRPs), improve the cost-effectiveness of therapeutic regimens and prevent hospitalizations.

Clinical Trial Description

Approximately 350,000 end-stage renal disease (ESRD) patients in the United States utilized over $17.9 billion Medicare dollars in 1999. The ESRD population and cost is projected to double by 2010. ESRD patients have a mean of 5 comorbidities per patient and are prescribed a median of eight medications. The average monthly medication cost per patient is approximately $1,200.00. For every dollar spent on medication an additional $1.77 is spent on drug-related problems (DRPs). Dialysis patients are at high risk for DRPs. It is unknown if continued pharmacist intervention in hemodialysis patients will improve patient care, reduce medication utilization and cost, and prevent hospitalization as seen in other populations. The purpose of this study is to investigate the impact of continued pharmacist intervention in ambulatory hemodialysis patients. ;

Related Conditions & MeSH terms

• End Stage Renal Disease
• Kidney Failure, Chronic

• NCT number: NCT05952388
• Study type: Interventional
• Source: University of New Mexico
• Status: Withdrawn
• Phase: N/A
• Start date: January 2003
• Completion date: January 2003